A LinkedIn post from Orasis Pharmaceuticals highlights the company’s planned presence at the SECO International 2026 conference, where its team is scheduled to appear at Booth 133. The post points to a focus on pilocarpine, with activities designed to address what are described as myths around the drug and to present data on low-concentration formulations.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, Orasis is promoting a breakfast symposium hosted by several optometrists with FAAO credentials, as well as a poster session on concentration-dependent effects of low-concentration pilocarpine. For investors, this emphasis suggests that Orasis is working to build clinical mindshare and reinforce the scientific narrative around its pilocarpine-based solutions, which could support future prescription uptake if its products gain or expand market access.
The educational positioning at a major optometry meeting may also indicate that Orasis is targeting eye‑care professionals as a primary channel for growth. Increased visibility at SECO 2026 could help differentiate its offerings in the competitive presbyopia and ocular therapeutics space, potentially strengthening its long-term commercialization prospects and partnership opportunities if the underlying data are positively received by clinicians.